Altimmune Inc is a biotechnology company focused on developing novel therapeutics for the treatment of liver diseases, respiratory infections, and immune-mediated disorders
The company's innovative approach includes the development of immunotherapeutics and vaccine candidates that aim to harness the body’s immune system to combat various health conditions. Altimmune employs advanced scientific techniques to create therapies that can improve patient outcomes and address unmet medical needs in the healthcare landscape. Through its research and development efforts, the company seeks to bring forward transformative treatments that enhance quality of life and offer new solutions for patients facing significant health challenges.
A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.
